Now Reading: Natco Pharma Q2 net profit down 60.9%, revenue falls 29%
-
01
Natco Pharma Q2 net profit down 60.9%, revenue falls 29%
The Story in Brief
Natco Pharma Ltd. reported a sharp year-on-year decline in its September quarter (Q2FY27) results on Friday, 13 November. Revenue fell 29% to ₹967.3 crore from ₹1,363 crore in the same quarter last year, while net profit dropped 60.9% to ₹202.6 crore from ₹518.4 crore. EBITDA declined 55.4% to ₹258 crore, with margin contracting to 26.6% from 42.5%.
The company's board declared a second interim dividend of ₹1.25 per equity share for FY27. The record date is 19 November 2026, and payment begins 27 November 2026. Natco also acquired an additional 13.25% stake in Adcock Ingram Holding Ltd during the quarter. Shares ended 0.22% lower at ₹807 on the BSE on Friday.
Indian Opinion Analysis
All three outlets reported the same core figures from Natco's regulatory filing, with minor variations in the year-ago net profit figure (₹518.4 crore in cnbctv18, ₹517.9 crore in Business Standard) and in the stock's closing price (₹801.45 in cnbctv18, ₹807 in Business Standard). cnbctv18 led with the dividend and stock performance, while Business Standard added the Adcock Ingram stake acquisition, and NDTV's brief report focused on the headline profit drop. None of the outlets offered commentary or context beyond the numbers, making the coverage uniformly straight reporting. The key divergence is the stock price movement, with cnbctv18 showing a 0.91% intraday decline and Business Standard a 0.22% close, reflecting different reporting times. The fourth item, the dividend record date of 19 November, remains the next concrete date for shareholders.
Coverage: 3 sources, 3 neutral
Sources (3): cnbctv18.com (neutral report), ndtv.com (neutral report), business-standard.com (neutral report)
This brief was synthesised by AI from the 3 sources linked above, so one read covers every framing they carry. Methodology and corrections.
